Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ensysce Biosciences Inc
(NQ:
ENSC
)
0.5700
-0.0200 (-3.39%)
Streaming Delayed Price
Updated: 3:55 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ensysce Biosciences Inc
< Previous
1
2
3
4
Next >
Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
Via
ACCESSWIRE
Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium
August 14, 2023
Via
ACCESSWIRE
Ensysce Biosciences Reports Second Quarter 2023 Financial Results
August 11, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces IRB Approval of Key Study Protocol
August 08, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Engagement of Alacrita Consulting
July 26, 2023
Via
ACCESSWIRE
Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo
June 27, 2023
Via
ACCESSWIRE
Ensysce Biosciences Regains Compliance with Nasdaq
June 13, 2023
Via
ACCESSWIRE
Ensysce Biosciences to Participate in Upcoming Industry Events
June 06, 2023
Via
ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2023 Financial Results
May 15, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection
May 09, 2023
Via
ACCESSWIRE
Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website
June 07, 2023
Via
ACCESSWIRE
Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering
May 12, 2023
Via
ACCESSWIRE
Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering
May 10, 2023
Via
ACCESSWIRE
Ensysce Biosciences (NASDAQ: ENSC) Successfully Completes Overdose-Protection Study
May 09, 2023
Ensysce Biosciences, Inc. (NASDAQ: ENSC) operates as a clinical-stage biotechnology company, which is focused on leveraging its proprietary technology to
Via
Spotlight Growth
Exposures
Product Safety
Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development
April 19, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website
April 11, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614
April 03, 2023
Via
ACCESSWIRE
Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
March 30, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study
March 22, 2023
Via
ACCESSWIRE
Dr. Lynn Kirkpatrick, Featured Speaker to Discuss Ensysce Overdose Protection Platform at DCAT Seminar
March 06, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock
February 28, 2023
Via
ACCESSWIRE
Ensysce Biosciences Provides Corporate Update
February 23, 2023
Via
ACCESSWIRE
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
February 15, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study
January 25, 2023
Via
ACCESSWIRE
Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting
February 14, 2023
Via
ACCESSWIRE
Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules
February 07, 2023
Via
ACCESSWIRE
Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering
February 03, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
February 01, 2023
Via
ACCESSWIRE
Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational
January 23, 2023
Via
ACCESSWIRE
Ensysce Biosciences Issues 2023 Shareholder Letter
January 11, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.